Olatec Therapeutics LLC

Efforts to unlock the potential of the NLRP3 inhibitor drugs and treat the so-called inflammasome has been ongoing for decades, but a new burst of investment could finally see the field deliver. One c

After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this m

Just four years after its foundation, Ireland's Inflazome Ltd. and its portfolio of NLRP3 inhibitors targeting a wide range of chronic inflammatory conditions has been acquired by Roche Holding AG